The following Federal Health Policy (FHP) Strategies Weekly Health Care Watch provides a summary of legislative and regulatory health care activities from November 8 – November 14. Where available, hyperlinks are included to the relevant documents. Please let us know if you have any questions or would like additional information on the items below.
LEGISLATIVE UPDATE
House
On November 10, Republicans elected Judiciary Committee Chairman Jim Jordan (R-OH) to serve as Minority Leader for the 120th Congress, defeating Majority Leader Steve Scalise (R-LA) by a vote of 106-73. Republicans also elected Majority Whip Tom Emmer (R-MN) as Minority Whip. Speaker Mike Johnson (R-LA) did not seek a leadership position in the new Congress.
On November 18, Democrats are scheduled to hold leadership elections with Minority Leader Hakeem Jeffries (D-NY) seeking the caucus’s nomination for Speaker.
Senate
On November 9, Sens. Raphael Warnock (D-GA), Ben Ray Luján (D-NM), and 14 other Democratic senators sent a letter to Finance Committee Chairman Mike Crapo (R-ID), Finance Committee Ranking Member Ron Wyden (D-OR), Majority Leader John Thune (R-SD), and Minority Leader Charles Schumer (D-NY) requesting a two-year delay of the Medicaid work requirements enacted in the One Big Beautiful Bill Act (OBBBA). The requirements are scheduled to take effect January 1, and the senators asked that the delay be included in the next moving legislative vehicle. The letter argued that states lack the time and resources to implement the requirements. It also argued that the Centers for Medicare & Medicaid Services (CMS) interim final rule implementing them adds requirements to the medical frailty definition beyond what the statute provides.
On November 10, the Appropriations Committee released the text of its Fiscal Year (FY) 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, which would provide a base discretionary total of $27.3 billion. The bill would provide nearly $7.3 billion for the Food & Drug Administration (FDA), with targeted increases for pharmaceutical competitiveness, global inspection capabilities, and food safety innovation. The bill also provides the discretionary funding needed to meet statutory requirements for continued FDA user fee funding and includes directives on the illegal importation and sale of e-cigarettes. Current government funding runs through December 11. The bill text can be found here. A summary of the bill text can be found here.
On November 10, Republicans reelected Majority Leader John Thune, who ran unopposed, as their leader.
On November 12, Sen. Chris Van Hollen (D-MD) announced that he will run for Majority Leader in the 120th Congress, challenging current Minority Leader Schumer for the position. Democrats will elect their leaders in early December.
On November 12, Sens. Sheldon Whitehouse (D-RI), Finance Committee Ranking Member Wyden, and Sen. Jon Ossoff (D-GA) sent letters to the Chief Executive Officers of six health insurers requesting information on their implementation of voluntary prior authorization commitments announced with the Trump Administration in June 2025. The letters, sent to UnitedHealthcare, Aetna, Cigna, Elevance Health, Blue Cross Blue Shield, and Humana, requested documentation on which services have been removed from prior authorization requirements, how changes have been communicated to patients and providers, and plans to implement remaining commitments. The senators also requested information on expected cost savings and how those savings will be reflected in premiums and benefits, with responses due December 4.
On November 12, Finance Committee Ranking Member Wyden and Sen. Angela Alsobrooks (D-MD) announced an investigation into whether Department of Health & Human Services (HHS) Secretary Robert F. Kennedy, Jr., made false statements to Congress about his 2019 trip to Samoa, which preceded a measles outbreak there. In a letter to Children's Health Defense, an organization Secretary Kennedy formerly chaired, the senators asserted that Secretary Kennedy's statement during his confirmation hearings that the trip had "nothing to do with vaccines" was false. The letter requested documents related to Secretary Kennedy's travel to Samoa and communications between Children's Health Defense and federal government officials, with responses due December 4. HHS stated in August that the trip was unrelated to vaccines. The letter can be found here.
On November 13, Finance Committee Ranking Member Wyden and five other Democratic senators sent a letter to CMS Administrator Dr. Mehmet Oz requesting information on CMS' compliance with federal Medicaid fraud prevention requirements. The letter argued that CMS has not maintained the minimum funding and staffing levels required by law for the Medicaid Integrity Program while increasing public enforcement actions against state Medicaid programs. The senators cited CMS' recent actions to withhold Medicaid funding from California and Minnesota and the HHS Office of Inspector General's (OIG) decertification of Medicaid Fraud Control Units in Hawaii and New York. The letter can be found here.
On November 13, Sen. Angus King (I-ME) announced the Protect U.S. Preventive Services Task Force Integrity Act, legislation to establish membership and conflict-of-interest standards for the U.S. Preventive Services Task Force (USPSTF). The bill would prioritize expertise in preventive and primary care medicine for USPSTF membership, establish conflict-of-interest and recusal requirements, and codify the USPSTF's April 2023 procedure manual, requiring public input on related changes. The bill would also prevent the HHS Secretary from changing USPSTF recommendations on the grounds that they no longer effectuate departmental standards. Sen. Elizabeth Warren (D-MA) is an original cosponsor. The bill text can be found here.
REGULATORY UPDATE
On November 9, CMS announced $10 billion in second-year awards to all 50 states under the Rural Health Transformation Program (RHTP). CMS stated that award amounts reflected, in part, its review of states’ annual progress reports, including implementation of state policies such as the Presidential Fitness Test and continuing medical education for physicians on nutrition. FY 2027 state awards range from approximately $142.3 million (New Jersey) to $282.0 million (Texas). HHS stated that total RHTP awards now reach $20 billion, with $30 billion remaining to be awarded over the final three years of the five-year program established by OBBBA. A fact sheet can be found here.
On November 9, HHS, through the Administration for Community Living (ACL), announced more than $9.7 million in awards to address elder abuse, neglect, and financial exploitation. The awards include six three-year Elder Justice Innovation Grants totaling $5.6 million, four two-year Legal Assistance Enhancement Program grants totaling $1.9 million, and grants to operate the National Long-Term Care Ombudsman Resource Center and the National Resource Center for Women and Retirement. ACL stated that the awards support federal elder justice efforts coordinated through the Elder Justice Coordinating Council.
On November 9, FDA approved Bayer’s Sunharbo (asundexian), a factor XIa (FXIa) inhibitor, for use with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. FDA stated that Sunharbo is the first approved FXIa inhibitor.
On November 9, FDA issued a Drug Safety Communication requiring application holders for all glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications to add information to the Warnings and Precautions section of labeling on a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). NAION is a rare condition that can cause permanent vision loss in one eye.
On November 10, FDA issued final guidance, titled “Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency.” The guidance covers validation of in vitro diagnostic tests when the HHS Secretary has declared that circumstances justify emergency use authorizations under the Federal Food, Drug, and Cosmetic Act. The guidance, which finalizes a January 2025 draft, outlines recommended clinical and analytical validation studies, including a general minimum of 30 positive and 30 negative specimens for clinical performance evaluations of certain molecular tests once clinical samples are available. It also addresses home use, point-of-care, and multi-analyte tests, and recommends that manufacturers consider developing change protocols for anticipated test modifications.
On November 12, Reuters reported that FDA has shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, citing six unnamed sources and internal documents. According to the report, FDA has awarded no new vouchers since former FDA Commissioner Dr. Marty Makary left the agency in May, and the executive council of political appointees that oversaw voucher reviews has gone dormant. An HHS spokesperson told Reuters that the pilot is ongoing and that FDA is reviewing feedback from a June public hearing to refine the program’s framework.
On November 12, HHS Secretary Kennedy announced up to $4.9 million over five years through the Advanced Research Projects Agency for Health (ARPA-H) to support development of ibogaine as a potential treatment for post-traumatic stress disorder (PTSD) and other serious mental illnesses, including among veterans. ARPA-H selected research teams led by Mark Cuban’s Cost Plus Drug Company to establish a foundation for a domestically manufactured ibogaine hydrochloride product and Beond, Inc. to provide clinical data on safety, dosing, efficacy, and durability. HHS stated that the awards will support preparation of Investigational New Drug (IND) applications and domestic manufacturing processes but do not fund patient treatment or human-subject research, authorize clinical trials, or establish FDA approval. The National Institute of Mental Health (NIMH) also published a $20 million Notice of Funding Opportunity to support development of a research network to study rapid-acting psychotropic interventional drugs (RAPIDs), such as ketamine, esketamine, and psilocybin, for serious mental illnesses.
On November 12, CMS issued notices extending and modifying the nationwide temporary moratoria on new Medicare enrollment of hospices and home health agencies (HHAs) for an additional six months, through May 12. The moratoria, which took effect May 13, will continue to apply to initial Medicare enrollment applications and certain changes in majority ownership, but, unlike the original moratoria, will allow currently enrolled hospices and HHAs to add practice locations within their existing enrollment. CMS stated that the extensions will not affect existing enrollments and are necessary for the agency to continue monitoring providers for indicators of fraud and to take administrative actions such as payment suspensions and revocations.
On November 13, CMS issued a State Medicaid Director letter offering states an optional "hold harmless" period through June 30, during which states may suspend eligibility denials and disenrollments when applicable individuals do not demonstrate compliance with the Medicaid community engagement requirements enacted in OBBBA. States using the option must still assess whether individuals meet or are excluded from the requirements and must obtain CMS approval through their state mitigation plans, and CMS asked states intending to begin the hold harmless period January 1 to notify CMS by December 11. CMS stated that failure to demonstrate community engagement will not count as an eligibility error in Payment Error Rate Measurement (PERM) reviews, Medicaid Eligibility Quality Control (MEQC) reviews, or other CMS Medicaid eligibility audits for applications filed or renewals initiated during the state’s approved hold harmless period.
WHITE HOUSE
On November 9, the White House Counsel’s Office sent a letter to House Oversight and Government Reform Committee Ranking Member Robert Garcia (D-CA) on constitutional limits to congressional investigations and subpoenas. Citing public statements by Rep. Garcia and other Democratic members and members-elect, the letter argued that the investigations those members described would lack a legitimate legislative purpose. The letter also stated that threats to executive branch officials, or subpoenas intended to intimidate, “may cross the line into blatant criminality.”
RULES AT THE WHITE HOUSE OFFICE OF MANAGEMENT & BUDGET (OMB)
Pending Review
CMS
Strengthening the Integrity of Medicaid and CHIP Managed Care, Financing, and Access to Care (CMS-2450); Proposed Rule; 05/12/2026
Short-Term, Limited-Duration Insurance (CMS-9881); Proposed Rule; 05/30/2026
Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (CMS-5546); Final Rule; 06/15/2026
Patient Protection and Affordable Care Act; State Innovation Waivers and Health Care Choice Compacts (CMS-9877); Proposed Rule; 07/13/2026
Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) (CMS-6098); Proposed Rule; 08/07/2026
Expanding Access to Individual Coverage Health Reimbursement Arrangements (CMS-9876); Proposed Rule; 10/05/2026
HHS Notice of Benefit and Payment Parameters for 2028 (CMS-9875); Proposed Rule; 10/19/2026
Contract Year 2028 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and PACE (CMS-4214); Proposed Rule; 10/26/2026
Medicare Drug Price Negotiation Program: Final Guidance, Manufacturer Effectuation of the Maximum Fair Price in 2028; Notice; 10/29/2026
CY 2027 Part A Premiums for the Uninsured Aged and for Certain Disabled Individuals Who Have Exhausted Other Entitlement (CMS-8093); Notice; 11/04/2026
Medicare Part B Monthly Actuarial Rates, Premium Rates, and Annual Deductible Beginning January 1, 2027 (CMS-8094); Notice; 11/04/2026
CY 2027 Inpatient Hospital Deductible and Hospital and Extended Care Services Coinsurance Amounts (CMS-8092); Notice; 11/04/2026
FDA
Cannabidiol (CBD) Products Compliance and Enforcement Policy; Notice; 03/13/2026
Administrative Detention of Tobacco Products; Proposed Rule; 07/09/2026
White Paper: Proposed Definition of Ultra-Processed Food; Notice; 08/03/2026
Use of Formaldehyde and Formaldehyde-Releasing Chemicals as an Ingredient in Hair Smoothing Products or Hair Straightening Products; Proposed Rule; 08/06/2026
Cheeses and Related Cheese Products; Proposal to Permit the Use of Ultrafiltered Milk and Microfiltered Milk; Final Rule; 08/28/2026
Sunlamp Products; Amendment to the Performance Standard; Final Rule; 09/09/2026
Clinical Trial Enrollment Action Plans to Improve Representation of the U.S. Intended Use Population in Clinical Studies; Notice; 10/06/2026
Labeling Caffeine Content in Foods and Beverages; Draft Guidance for Industry; Notice; 11/06/2026
Section 505(b)(2) Applications Proposing Nonprescription Use; Request for Information; Notice; 11/06/2026
HEARINGS
Senate
HELP Committee
November 18; 9:45 AM; 430 Dirksen
Nominees: Mark Priebe to be Inspector General, Department of Education; Heidi Overton to be Commissioner of Food and Drugs, HHS; Michael Doyle to be a Member of the Occupational Safety and Health Review Commission; Catherine Eschbach to be General Counsel of the Equal Employment Opportunity Commission; James O'Neill to be Director of the National Science Foundation
REPORTS
Office of Inspector General (OIG)
On November 10, HHS OIG released an audit finding that non-state government-owned entities recovered $480 million of the approximately $1 billion in Medicaid nursing facility supplemental payments Indiana reported in federal fiscal year 2022. OIG found that $205 million of that amount was not used to increase Medicaid reimbursement for participating nursing facilities as intended and that Indiana claimed $12 million in federal payments that did not comply with federal and state requirements. OIG made four recommendations to Indiana, including that it refund the $12 million to the federal government and explore ways to increase the share of supplemental payments that participating nursing facilities retain. Indiana did not indicate whether it concurred with the recommendations but described steps it has taken and plans to take in response.
On November 10, HHS OIG released an audit summarizing six previous OIG audits of Medicare administrative contractors' (MACs) cost report settlement processes and found that CMS oversight of those processes was not adequate. OIG stated that the prior audits identified 234 cost report reopenings resulting from MAC audit or desk review errors, with corrected final settlements totaling $31.6 million, of which CMS' quality assurance process had identified eight. OIG made three recommendations to CMS, including that it require MACs to submit annual reports on the numbers and types of errors identified in final settlements. CMS concurred with one recommendation, did not concur with one, and did not specifically concur or nonconcur with the third.
Government Accountability Office (GAO)
On November 9, GAO released a report finding that all Medicare Part D enrollees in 2025 and all Medicaid enrollees in 2024 had coverage of some form of naloxone, while coverage of nalmefene, a newer and longer-acting opioid overdose reversal medication, was less common. GAO found that Part D plans generally did not cover over-the-counter (OTC) naloxone nasal sprays in 2025, while Medicaid covered them in 2024. GAO also found that Part D out-of-pocket costs varied by formulation and brand or generic status, ranging from a $3 to $10 median copay for generic naloxone injections to a 25 to 35% median coinsurance for brand high-dose naloxone and nalmefene nasal sprays. In four selected states, Medicaid enrollees had either no copays or copays of less than $5.
ADDITIONAL POLICY NEWS
On November 6, the Biotechnology Innovation Organization (BIO), Biocom, and California Life Sciences filed a complaint in the U.S. District Court for the Northern District of California challenging the CMS final rule establishing the Global Benchmark for Efficient Drug Pricing (GLOBE) Model. The model is scheduled to begin January 1 and would require manufacturers of certain Medicare Part B drugs to pay rebates when U.S. prices exceed an international benchmark. The complaint alleges that CMS exceeded its statutory authority to test payment model, and that the rule violates appropriations law and the separation of powers and nondelegation doctrines.
On November 6, Hims & Hers and Eli Lilly and Company announced an agreement to offer Zepbound (tirzepatide) and Foundayo (orforglipron), Lilly’s daily oral GLP-1 medicine, through the Hims & Hers telehealth platform. Eligible patients can complete a consultation, receive a prescription if clinically appropriate, and arrange home delivery without leaving the platform, at the same self-pay prices available to other patients. Hims & Hers stated that it has never offered compounded copies of Lilly’s GLP-1 medicines and committed not to do so in the future.